Last $8.14 USD
Change Today -0.105 / -1.27%
Volume 1.7M
PDLI On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

pdl biopharma inc (PDLI) Snapshot

Open
$8.23
Previous Close
$8.24
Day High
$8.23
Day Low
$8.01
52 Week High
09/2/14 - $10.26
52 Week Low
10/7/14 - $7.22
Market Cap
1.3B
Average Volume 10 Days
2.0M
EPS TTM
$1.98
Shares Outstanding
160.7M
EX-Date
12/3/14
P/E TM
4.1x
Dividend
$0.60
Dividend Yield
7.37%
Current Stock Chart for PDL BIOPHARMA INC (PDLI)

Related News

No related news articles were found.

pdl biopharma inc (PDLI) Related Businessweek News

No Related Businessweek News Found

pdl biopharma inc (PDLI) Details

PDL BioPharma, Inc. manages a portfolio of patents and royalty assets. The company is involved in the humanization of monoclonal antibodies and the discovery of a new generation of targeted treatments for cancer and immunologic diseases. It offers Queen et al. patents that cover humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies, and methods of producing humanized antibodies. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.

10 Employees
Last Reported Date: 11/10/14
Founded in 1986

pdl biopharma inc (PDLI) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $1.2M
Chief Financial Officer and Vice President
Total Annual Compensation: $323.2K
Vice President, General Counsel and Secretary
Total Annual Compensation: $659.7K
Chief Accounting Officer and Controller
Total Annual Compensation: $105.0K
Vice President of Business Development
Total Annual Compensation: $509.6K
Compensation as of Fiscal Year 2013.

pdl biopharma inc (PDLI) Key Developments

PDL BioPharma, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

PDL BioPharma, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. Total revenues for the third quarter of 2014 increased approximately 64% to $164.6 million from $100.2 million in the third quarter of 2013. Net income in the third quarter of 2014 was $102.2 million, or $0.61 per diluted share, as compared with net income in the third quarter of 2013 of $56.2 million, or $0.36 per diluted share. Operating income was $158,908,000 against $92,253,000 a year ago. Income before income taxes was $149,596,000 against $86,188,000 a year ago. Total revenues for the first nine months of 2014 increased 35% to $464.2 million, compared with $344.3 million for the first nine months of 2013. The increase for the nine month period of 2014 over 2013 is primarily driven by the addition of the royalty payments from PDL's purchase of Depomed's diabetes-related royalties, increased royalties in the first three quarters of 2014 related to sales of Avastin(R), Herceptin(R), Xolair(R), Kadcyla(R), Perjeta(R), Tysabri(R) and Actemra(R), along with a higher fixed royalty rate in 2014 over the blended fixed and tiered 2013 rate, a $23.2 million increase in interest revenue related to acquisitions of new revenue generating assets, and a $5.0 million retroactive payment in first quarter of 2014 related to settlement agreement with Genentech, partially offset by a higher foreign exchange loss and higher rebate paid to Novartis AG for Lucentis. Net income for the first nine months of 2014 was $267.2 million, or $1.62 per diluted share, as compared with net income in the first nine months of 2013 of $203.4 million, or $1.31 per diluted share. Net cash provided by operating activities in the first nine months of 2014 was $223.2 million, compared with $208.5 million in the first nine months of 2013. Operating income was $446,962,000 against $322,400,000 a year ago. Income before income taxes was $411,256,000 against $304,433,000 a year ago.

PDL BioPharma, Inc. to Report Q3, 2014 Results on Nov 10, 2014

PDL BioPharma, Inc. announced that they will report Q3, 2014 results at 3:00 PM, Eastern Standard Time on Nov 10, 2014

PDL BioPharma, Inc., Q3 2014 Earnings Call, Nov 10, 2014

PDL BioPharma, Inc., Q3 2014 Earnings Call, Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDLI:US $8.14 USD -0.105

PDLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
arGEN-X BV €7.40 EUR +0.38
BioInvent International AB kr2.88 SEK +0.04
Genmab A/S kr295.90 DKK +0.50
XOMA Corp $5.70 USD +0.18
View Industry Companies
 

Industry Analysis

PDLI

Industry Average

Valuation PDLI Industry Range
Price/Earnings 4.2x
Price/Sales 2.8x
Price/Book 3.3x
Price/Cash Flow 4.0x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PDL BIOPHARMA INC, please visit www.pdl.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.